Citation APA
Lafeuillade, A., Clumeck, N., Mallolas, J., Jaeger, H., Livrozet, J.-M., do Sameira Ferreira, M., Johnson, M., Cheret, A., Antoun, Z., Demonty, J., Bazin, C., Bentata, M., Bouvet, É., Delfraissy, J., Dellamonica, P., Saint Marc, T., De Saint Martin, L., De Truchis, P., Dien, G., Gallais, H., Gil, H., Hoen, B., Katlama, C., Lacoste, D., Lang, J., Beumont, M., Massip, P., Rozenbaum, W., Sereni, D., Yeni, P., Fenske, S., Rockstroh, J., Salzberger, B., Schuermann, D., Staszewski, S., Mulcahy, F., Lazzarin, A., Milazzo, F., Moroni, M., Cargnel, A., Santos, C. P., Flamholc, L., Koppel, K., Easterbrook, P., Fisher, M., Gazzard, B., Kinghorn, G., Weber, J., & Wilkins, E. (2003). Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir™ versus continued HAART: The trizal study. HIV clinical trials, 4(1), 37-43. doi:10.1310/EJRF-JGGH-GRCD-MED8
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/84790